A prespecified primary aim was to assess the degree to which the MGI+HOXB13:IL17BR risk classifier predicts the risk of breast cancer-specific mortality among tamoxifen-treated ER-positive, node-negative patients, either alone or after accounting for tumor size and tumor grade. Here, IL17RB is linked to neoplasm.